- 著者
- Shotaro Ide Noriho Sakamoto Shintaro Hara Atsuko Hara Tomoyuki Kakugawa Yoichi Nakamura Yoji Futsuki Koichi Izumikawa Yuji Ishimatsu Katsunori Yanagihara Hiroshi Mukae
- 出版者
- 一般社団法人 日本内科学会
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- vol.56, no.1, pp.79-83, 2017-01-01 (Released:2017-01-01)
- 参考文献数
- 20
- 被引用文献数
- 4
Although pneumothorax has been reported to be a major pulmonary adverse event in patients treated with pazopanib, a multikinase inhibitor, drug-induced interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese man who received pazopanib for the treatment of femoral leiomyosarcoma and lung metastasis presented with dyspnea and fatigue. He had mild interstitial pneumonia when pazopanib treatment was initiated. Chest computed tomography revealed progressive bilateral ground-glass opacity (GGO) and traction bronchiectasis. We diagnosed DILD due to pazopanib. The patient's pazopanib treatment was interrupted and a steroid was administered. The symptoms and GGO were improved with treatment. Physicians should be aware of DILD due to pazopanib in patients with pre-existing interstitial lung disease.
- 著者
- Noriho Sakamoto Hiroshi Ishimoto Shota Nakashima Hirokazu Yura Takuto Miyamura Daisuke Okuno Atsuko Hara Takeshi Kitazaki Tomoyuki Kakugawa Yuji Ishimatsu Minoru Satoh Hiroshi Mukae
- 出版者
- The Japanese Society of Internal Medicine
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- vol.58, no.6, pp.837-841, 2019-03-15 (Released:2019-03-15)
- 参考文献数
- 19
- 被引用文献数
- 23
Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody is associated with rapidly progressive interstitial lung disease (RP-ILD) in patients with clinically amyopathic dermatomyositis (CADM) or dermatomyositis (DM). We herein report three Japanese cases of anti-MDA5 antibody-positive RP-ILD without signs of CADM or DM. High-resolution computed tomography revealed patchy or subpleural distribution of consolidations and/or ground-glass opacities accompanied by traction bronchiectasis. All patients succumbed to respiratory failure within two months. Anti-MDA5 antibody-positive RP-ILD without signs of CADM or DM should be included in the differential diagnosis of acute/subacute ILD. Measurement of anti-MDA5 antibody and an intensive immunosuppressive regimen might rescue these patients from RP-ILD.